Clearside Biomedical (CLSD) IPO Opens Up 14%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Clearside Biomedical (CLSD) Prices 7.2M Common Stock IPO at $7/Share
June 2, 2016 6:57 AM EDTClearside Biomedical, Inc. (Nasdaq: CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of $7.00 per share. In addition, Clearside has granted the underwriters a 30-day option to purchase up to an additional 1,080,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The shares are scheduled to begin trading on the NASDAQ Global Market on June 2, 2016 under the ticker... More



